Afficher la notice abrégée

dc.contributor.authorBalzerani, Francesco
dc.contributor.authorHinojosa Nogueira, Daniel José 
dc.contributor.authorPérez Burillo, Sergio 
dc.contributor.authorRufián Henares, José Ángel 
dc.date.accessioned2022-07-14T09:22:09Z
dc.date.available2022-07-14T09:22:09Z
dc.date.issued2022-07-12
dc.identifier.urihttp://hdl.handle.net/10481/76013
dc.description.abstractThe relevance of phenolic compounds in the human diet has increased in recent years, particularly due to their role as natural antioxidants and chemopreventive agents in different diseases. In the human body, phenolic compounds are mainly metabolized by the gut microbiota; however, their metabolism is not well represented in public databases and existing reconstructions. In a previous work, using different sources of knowledge, bioinformatic and modelling tools, we developed AGREDA, an extended metabolic network more amenable to analyze the interaction of the human gut microbiota with diet. Despite the substantial improvement achieved by AGREDA, it was not sufficient to represent the diverse metabolic space of phenolic compounds. In this article, we make use of an enzyme promiscuity approach to complete further the metabolism of phenolic compounds in the human gut microbiota. In particular, we apply RetroPath RL, a previously developed approach based on Monte Carlo Tree Search strategy reinforcement learning, in order to predict the degradation pathways of compounds present in Phenol-Explorer, the largest database of phenolic compounds in the literature. Reactions predicted by RetroPath RL were integrated with AGREDA, leading to a more complete version of the human gut microbiota metabolic network. We assess the impact of our improvements in the metabolic processing of various foods, finding previously undetected connections with output microbial metabolites. By means of untargeted metabolomics data, we present in vitro experimental validation for output microbial metabolites released in the fermentation of lentils with feces of children representing different clinical conditions.es_ES
dc.language.isoenges_ES
dc.publisherSpringer-Naturees_ES
dc.rightsAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.titlePrediction of degradation pathways of phenolic compounds in the human gut microbiota through enzyme promiscuity methodses_ES
dc.typejournal articlees_ES
dc.relation.projectIDThis work was funded by the European Union’s Horizon 2020 research and innovation programme through the STANCE4HEALTH project (Grant No. 816303)es_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doihttps://doi.org/10.1038/s41540-022-00234-9
dc.type.hasVersionVoRes_ES


Fichier(s) constituant ce document

[PDF]

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée

Atribución-NoComercial-CompartirIgual 4.0 Internacional
Excepté là où spécifié autrement, la license de ce document est décrite en tant que Atribución-NoComercial-CompartirIgual 4.0 Internacional